Please login to the form below

edoxaban

This page shows the latest edoxaban news and features for those working in and with pharma, biotech and healthcare.

Bad news for Portola as CHMP considers Factor Xa drugs

Eliquis (apixaban), Bayer/Johnson &Johnson's Xarelto (rivaroxaban) and Daiichi Sankyo's Lixiana/Savaysa (edoxaban) - have thus far not been approved.

Latest news

Xarelto no better than aspirin in secondary stroke study

Savaysa (edoxaban) some way behind in third and fourth place, respectively.
Xarelto beats aspirin for recurrent blood clots

edoxaban). Xarelto has slipped from a 60%-plus market share, however, with Eliquis gaining ground in part because of a debate about Xarelto's role in stroke prevention and the design
Portola rejection hands advantage to Boehringer's Pradaxa

Johnson &Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.
Boehringer starts to feel impact of Spiriva generics

Squibb's Eliquis (apixaban) and Daiichi Sankyo's recently-approved Savaysa (edoxaban).
BMS claims 80% market share for Opdivo in US

and Daiichi Sankyo's Savaysa (edoxaban) in both atrial fibrillation (AF) and venous thromboembolism (VTE), according to the company.

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Modern anticoagulants threaten status quo

trial. Edoxaban. Edoxaban (Lixiana; Daiichi Sankyo) is an oral, once-daily, selective factor Xa inhibitor approved in Japan for prevention of VTE following major orthopaedic surgery. ... Daiichi Sankyo is conducting a large, worldwide, phase III trial of

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Home based, Senior Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Business Unit Head, Medical Communications, London: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Healthcare PR Director: £100, 000 – £120, 000 benefits

Home based, Editorial Team Leader, Medical Communications: Excellent package

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Client Services Director – Healthcare Advertising - London: Neg

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Client Services Director - Med Comms: Great salary and bebefits

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Senior Account Manager: Competitive salary commensurate with experience

Subscribe to our email news alerts

PMHub

Add my company

Genetic Digital

We help healthcare, pharma & medical device organisations use web and mobile technologies to effectively connect patients and healthcare professionals....

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....